stockrowDexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
Follow DXCM
Alert me
DexCom, Inc. (DXCM) Return on equity
DexCom, Inc.'s return on equity over the twelve months to 30 September 2026 was 37.7%, up 3.2 percentage points from fiscal 2025 (34.5%). Over the past ten years it has ranged from −31.9% (fiscal 2015) to 40.6% (fiscal 2020); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 34.5% | 6.87 |
| FY2024 | 27.6% | 1.85 |
| FY2023 | 25.8% | 9.43 |
| FY2022 | 16.4% | 5.14 |
| FY2021 | 11.2% | (29.37) |
| FY2020 | 40.6% | 27.50 |
| FY2019 | 13.1% | 36.56 |
| FY2018 | −23.5% | (9.20) |
| FY2017 | −14.3% | 11.70 |
| FY2016 | −26.0% | 5.90 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| DXCM DexCom, Inc. | 37.7% |
| GEHC GE HealthCare Technologies Inc. compare | 19.9% |
| BSX Boston Scientific Corporation compare | 14.2% |
| STE STERIS plc compare | 11.6% |
| EW Edwards Lifesciences Corporation compare | 9.65% |
| PHG Koninklijke Philips N.V. compare | 8.54% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 6.02% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| GKOS Glaukos Corporation compare | −22.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement